ClinicalTrials.gg
CompletedNCT01407016Updated Sep 28, 2011

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects

A Phase 1 interventional study of metronidazole IV 500 mg in Infection, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.

02

Conditions studied

  • Infection

Browse trials for

Keywords

  • metronidazole infusion
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 6 is below the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male and/or female subjects.

Exclusion criteria

Exclusion Criteria:

  • Subject with evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Subject with history of regular alcohol consumption exceeding 7 drink/week for females or 14 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months of screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    1.0

    Drug: metronidazole IV 500 mg

Interventions

  • On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.

06

What researchers measure

Primary outcomes

  1. Plasma metronidazole pharmacokinetic parameters for single dose:Cmax

    Time frame: Day 1 to Day 3

  2. Plasma metronidazole pharmacokinetic parameters for single dose:AUClast

    Time frame: Day 1 to Day 3

  3. Plasma metronidazole pharmacokinetic parameters for single dose:AUC0-6

    Time frame: Day 1 to Day 3

  4. Plasma metronidazole pharmacokinetic parameters for single dose:Tmax

    Time frame: Day 1 to Day 3

  5. Plasma metronidazole pharmacokinetic parameters for multiple dose:Ctrough

    Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8

  6. Plasma metronidazole pharmacokinetic parameters for multiple dose:Cmax

    Time frame: Day 8 to Day 9

  7. Plasma metronidazole pharmacokinetic parameters for multiple dose:AUC0-6

    Time frame: Day 8 to Day 9

  8. Plasma metronidazole pharmacokinetic parameters for multiple dose:Tmax

    Time frame: Day 8 to Day 9

  9. Plasma metronidazole pharmacokinetic parameters for multiple dose:CL

    Time frame: Day 8 to Day 9

Secondary outcomes

  1. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Cmax

    Time frame: Day 1 to Day 3

  2. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUClast

    Time frame: Day 1 to Day 3

  3. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: AUC0-6

    Time frame: Day 1 to Day 3

  4. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for single dose: Tmax

    Time frame: Day 1 to Day 3

  5. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Ctrough

    Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8

  6. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Cmax

    Time frame: Day 8 to Day 9

  7. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: AUC0-6

    Time frame: Day 8 to Day 9

  8. Plasma 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole pharmacokinetic parameters for multiple dose: Tmax

    Time frame: Day 8 to Day 9

07

Study locations

1 site
  • Pfizer Investigational Site
    Tokyo, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2011
First posted
Aug 1, 2011
Start
Aug 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Sep 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01407016
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 1, 2011
Start date
Aug 2011
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Sep 28, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion